Frontier Pharma: Systemic Lupus Erythematosus - Identifying and ... PR Newswire (press release) ... Benlysta (belimumab), generated sales of $111m in 2012, there is little evidence that the drug's performance is significantly superior to other B-cell targeted therapies such as Rituxan (rituximab), which is often used off-license to treat ... |
